Krystiana A Krzysko
Overview
Explore the profile of Krystiana A Krzysko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
161
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krajewska J, Chyzy P, Durka K, Winska P, Krzysko K, Lulinski S, et al.
Molecules
. 2023 Nov;
28(21).
PMID: 37959781
Over 30 compounds, including -, -, and -phenylenediboronic acids, -substituted phenylboronic acids, benzenetriboronic acids, di- and triboronated thiophenes, and pyridine derivatives were investigated as potential β-lactamase inhibitors. The highest activity...
2.
Charzewski L, Krzysko K, Lesyng B
Front Mol Biosci
. 2021 Aug;
8:633181.
PMID: 34434961
Recently, molecular covalent docking has been extensively developed to design new classes of inhibitors that form chemical bonds with their biological targets. This strategy for the design of such inhibitors,...
3.
Charzewski L, Krzysko K, Lesyng B
Sci Rep
. 2021 Jun;
11(1):13376.
PMID: 34183752
MMP-9 plays a number of important physiological functions but is also responsible for many pathological processes, including cancer invasion, metastasis, and angiogenesis. It is, therefore, crucial to understand its enzymatic...
4.
Durka K, Laudy A, Charzewski L, Urban M, Stepien K, Tyski S, et al.
Eur J Med Chem
. 2019 Mar;
171:11-24.
PMID: 30904754
A series of 22 benzosiloxaboroles, silicon analogues of strong antimicrobial agents - benzoxaboroles, have been synthesized and tested against β-lactamases KPC- and pAmpC-producing strains of Gram-negative rods. Comprehensive structural-property relationship...
5.
Beresewicz M, Charzewski L, Krzysko K, Kochanski A, Zablocka B
Sci Rep
. 2018 Nov;
8(1):16900.
PMID: 30442897
Charcot-Marie-Tooth disease type 2A (CMT2A) is an autosomal dominant neuropathy caused by mutations in the mitofusin 2 gene (MFN2). More than 100 MFN2 gene mutations have been reported so far,...
6.
Beresewicz M, Boratynska-Jasinska A, Charzewski L, Kawalec M, Kabzinska D, Kochanski A, et al.
PLoS One
. 2017 Jan;
12(1):e0169999.
PMID: 28076385
Charcot-Marie-Tooth disease type 2A (CMT2A) is an autosomal dominant axonal peripheral neuropathy caused by mutations in the mitofusin 2 gene (MFN2). Mitofusin 2 is a GTPase protein present in the...
7.
Mielecki M, Milner-Krawczyk M, Grzelak K, Mielecki D, Krzysko K, Lesyng B, et al.
Curr Cancer Drug Targets
. 2014 Aug;
14(7):638-51.
PMID: 25146330
Scaffold-based analogs of cinnamic acid benzyl amide (CABA) exhibit pleiotropic effects in cancer cells, and their exact molecular mechanism of action is under investigation. The present study is part of...
8.
Ishikawa T, Krzysko K, Kowalska-Loth B, Skrajna A, Czubaty A, Girstun A, et al.
Biochemistry
. 2012 Feb;
51(8):1803-16.
PMID: 22320324
Human DNA topoisomerase I (topo I) catalyzes DNA relaxation and phosphorylates SRSF1. Whereas the structure of topo I complexed with DNA has been resolved, the structure of topo I in...
9.
Ahmed A, Goldsmith J, Fokt I, Le X, Krzysko K, Lesyng B, et al.
Cancer Chemother Pharmacol
. 2011 Feb;
68(4):1033-44.
PMID: 21340606
Purpose: To investigate the mechanistic basis of the anti-tumor effect of the compound ITB-301. Methods: Chemical modifications of genistein have been introduced to improve its solubility and efficacy. The anti-tumor...
10.
Jozwiak K, Krzysko K, Bojarski L, Gacia M, Filipek S
ChemMedChem
. 2007 Dec;
3(4):627-34.
PMID: 18061918
Gamma-secretase is an integral membrane protease, which is a complex of four membrane proteins. Improper functioning of gamma-secretase was found to be critical in the pathogenesis of Alzheimer's disease. Despite...